Balancing osteogenesis and adipogenesis in osteogenesis imperfecta: PLIN2 and E2F2 as key targets for mesenchymal stem cell therapy
Advances in Clinical and Experimental Medicine · 26.05.2026 · 35 (5) · 835-846
DOI: 10.17219/acem/208840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, online erschienen am 26.05.2026. Verfasst von Xishun Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Capital Center for Children's Health, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Osteogenesis Imperfecta, Adipogenesis, Osteogenesis, Perilipin-2. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Osteogenesis imperfecta (OI) necessitates innovative mesenchymal stem cell (MSC) therapies targeting key molecular pathways to enhance targeted and combination treatments and improve bone health. OBJECTIVES: To investigate the therapeutic mechanisms of various interventions for OI by analyzing relevant datasets, with a focus on lipid metabolism-related genes, particularly PLIN2, in order to determine whether they influence the balance between osteoblast and adipocyte differentiation. MATERIAL AND METHODS: This study analyzed datasets from the Gene Expression Omnibus (GEO; GSE157587, GSE214064, GSE186141) and UK Biobank genome-wide association study (GWAS) summary statistics (UKB-b-4657, UKB-b-1096, UKB-b-8875, UKB-b-20124) using bioinformatics tools, including GEO2R, DESeq2, TwoSampleMR, MR-Egger, MR-PRESSO, gwasrapidd, and summary data-based Mendelian randomization (MR), to identify differentially expressed genes (DEGs) and assess causal relationships with heel bone mineral density (BMD). RESULTS: Differentially expressed genes analysis of GSE157587 identified PLIN2 as the most significant gene influenced by MSC therapy in OI (log2 fold change = 0.428, adjusted p = 3.29 × 10-6), whereas GSE186141 revealed 770 DEGs in OI patients, with 7 overlapping with PLIN2-related genes. Notably, TNFRSF19 (log2 fold change = -2.7454, adjusted p = 3.930 × 10-7 in OI; 1.5001, adjusted p = 3.482 × 10-3 in PLIN2 knockdown) and E2F2 (log2 fold change = -2.1428, adjusted p = 8.830 × 10-5 in OI; 1.7207, adjusted p = 1.244 × 10-2 in PLIN2 knockdown) were identified as key genes. Mendelian randomization analysis confirmed a negative association between E2F2 and heel BMD (p = 1.116 × 10-7 to 6.073 × 10-5; effect size -0.0461 to -0.0277). CONCLUSIONS: PLIN2 and E2F2 emerge as critical targets for refining MSC therapy in OI, with the potential to improve bone formation and reduce fat accumulation by restoring the osteogenesis-adipogenesis balance. These findings may support the development of combination therapies or engineered MSCs, ultimately improving clinical outcomes for patients with OI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Capital Center for Children's Health, Capital Medical University, Beijing, China.
Zitieren
APA
Wang, X., Liu, Z., Hu, X., & Cui, Y. (2026). Balancing osteogenesis and adipogenesis in osteogenesis imperfecta: PLIN2 and E2F2 as key targets for mesenchymal stem cell therapy. Advances in Clinical and Experimental Medicine, 35(5), 835-846. https://doi.org/10.17219/acem/208840
Vancouver
Wang X, Liu Z, Hu X, Cui Y. Balancing osteogenesis and adipogenesis in osteogenesis imperfecta: PLIN2 and E2F2 as key targets for mesenchymal stem cell therapy. Advances in Clinical and Experimental Medicine. 2026;35(5):835-846. doi:10.17219/acem/208840
BibTeX
@article{Wang2026,
author = {Wang, Xishun and Liu, Zhenjiang and Hu, Xinyong and Cui, Yinpeng},
title = {Balancing osteogenesis and adipogenesis in osteogenesis imperfecta: PLIN2 and E2F2 as key targets for mesenchymal stem cell therapy},
journal = {Advances in Clinical and Experimental Medicine},
year = {2026},
volume = {35},
number = {5},
pages = {835--846},
doi = {10.17219/acem/208840}
}
EUVIMED